Skip to main content
. 2016 Jul 4;4(6):457–465. doi: 10.1007/s40336-016-0197-4

Fig. 3.

Fig. 3

uPAR PET imaging of patients with newly diagnosed prostate cancer. Representative transverse CT, PET, and co-registered PET/CT images from the first-ever uPAR PET study in humans. Upper panel shows a primary tumor lesion (blue arrow) with high uptake of 64Cu-DOTA-AE105. uPAR immunohistochemistry on surgically removed prostate cancer tissue confirmed general pattern of uPAR expression. Bottom images show a uPAR-positive regional lymph node metastasis (blue arrow) with high 64Cu-DOTA-AE105 uptake. The subsequent staging operation and histopathological assessment confirmed prostate adenocarcinoma in three out of six removed lymph nodes.

Reproduced from [44] with permission